Fludarabine and 2-Gy TBI is superior to 2Gy TBI as conditioning for HLA-Matched related hematopoietic cell transplantation: A phase III randomized trial

Brian Kornblit, David G. Maloney, Rainer Storb, Jan Storek, Parameswaran Hari, Vladan Vucinic, Richard Maziarz, Thomas R. Chauncey, Michael A. Pulsipher, Benedetto Bruno, Finn B. Petersen, Wolfgang A. Bethge, Kai Hübel, Michelle E. Bouvier, Takahiro Fukuda, Barry E. Storer, Brenda M. Sandmaier

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in combination with 90mg/m2 fludarabine (FLU/TBI), before transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five patients with hematological malignancies were randomized to be conditioned with TBI alone (n=44) or FLU/TBI (n=41). All patients had initial engraftment. Two graft rejections were observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host disease (GVHD) were similar between groups. Three-year overall survival was lower in the TBI group (54% versus 65%; hazard ratio [HR], .57; P= .09), with higher incidences of relapse/progression (55% versus 40%; HR, .55; P= .06), relapse-related mortality (37% versus 28%; HR, .53; P= .09), and a lower progression-free survival (36% versus 53%; HR, .56; P= .05). Median donor T cell chimerism levels were significantly lower in the TBI group at days 28 (61% versus 90%; P

Original languageEnglish (US)
Pages (from-to)1340-1347
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Whole-Body Irradiation
Cell Transplantation
Tissue Donors
Peripheral Blood Stem Cell Transplantation
Recurrence
Chimerism
Mortality
fludarabine
Graft Rejection
Graft vs Host Disease
Hematologic Neoplasms
Disease-Free Survival
T-Lymphocytes
Survival
Incidence
Infection

Keywords

  • Body irradiation
  • Fludarabine/low dose total
  • Hematopoietic cell
  • HLA-matched related
  • Nonmyeloablative conditioning
  • Transplantation randomized
  • Trial

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

Fludarabine and 2-Gy TBI is superior to 2Gy TBI as conditioning for HLA-Matched related hematopoietic cell transplantation : A phase III randomized trial. / Kornblit, Brian; Maloney, David G.; Storb, Rainer; Storek, Jan; Hari, Parameswaran; Vucinic, Vladan; Maziarz, Richard; Chauncey, Thomas R.; Pulsipher, Michael A.; Bruno, Benedetto; Petersen, Finn B.; Bethge, Wolfgang A.; Hübel, Kai; Bouvier, Michelle E.; Fukuda, Takahiro; Storer, Barry E.; Sandmaier, Brenda M.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 9, 09.2013, p. 1340-1347.

Research output: Contribution to journalArticle

Kornblit, B, Maloney, DG, Storb, R, Storek, J, Hari, P, Vucinic, V, Maziarz, R, Chauncey, TR, Pulsipher, MA, Bruno, B, Petersen, FB, Bethge, WA, Hübel, K, Bouvier, ME, Fukuda, T, Storer, BE & Sandmaier, BM 2013, 'Fludarabine and 2-Gy TBI is superior to 2Gy TBI as conditioning for HLA-Matched related hematopoietic cell transplantation: A phase III randomized trial', Biology of Blood and Marrow Transplantation, vol. 19, no. 9, pp. 1340-1347. https://doi.org/10.1016/j.bbmt.2013.06.002
Kornblit, Brian ; Maloney, David G. ; Storb, Rainer ; Storek, Jan ; Hari, Parameswaran ; Vucinic, Vladan ; Maziarz, Richard ; Chauncey, Thomas R. ; Pulsipher, Michael A. ; Bruno, Benedetto ; Petersen, Finn B. ; Bethge, Wolfgang A. ; Hübel, Kai ; Bouvier, Michelle E. ; Fukuda, Takahiro ; Storer, Barry E. ; Sandmaier, Brenda M. / Fludarabine and 2-Gy TBI is superior to 2Gy TBI as conditioning for HLA-Matched related hematopoietic cell transplantation : A phase III randomized trial. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 9. pp. 1340-1347.
@article{adbe9ccf39c64c5587c5fa6ec8254c2b,
title = "Fludarabine and 2-Gy TBI is superior to 2Gy TBI as conditioning for HLA-Matched related hematopoietic cell transplantation: A phase III randomized trial",
abstract = "The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in combination with 90mg/m2 fludarabine (FLU/TBI), before transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five patients with hematological malignancies were randomized to be conditioned with TBI alone (n=44) or FLU/TBI (n=41). All patients had initial engraftment. Two graft rejections were observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host disease (GVHD) were similar between groups. Three-year overall survival was lower in the TBI group (54{\%} versus 65{\%}; hazard ratio [HR], .57; P= .09), with higher incidences of relapse/progression (55{\%} versus 40{\%}; HR, .55; P= .06), relapse-related mortality (37{\%} versus 28{\%}; HR, .53; P= .09), and a lower progression-free survival (36{\%} versus 53{\%}; HR, .56; P= .05). Median donor T cell chimerism levels were significantly lower in the TBI group at days 28 (61{\%} versus 90{\%}; P",
keywords = "Body irradiation, Fludarabine/low dose total, Hematopoietic cell, HLA-matched related, Nonmyeloablative conditioning, Transplantation randomized, Trial",
author = "Brian Kornblit and Maloney, {David G.} and Rainer Storb and Jan Storek and Parameswaran Hari and Vladan Vucinic and Richard Maziarz and Chauncey, {Thomas R.} and Pulsipher, {Michael A.} and Benedetto Bruno and Petersen, {Finn B.} and Bethge, {Wolfgang A.} and Kai H{\"u}bel and Bouvier, {Michelle E.} and Takahiro Fukuda and Storer, {Barry E.} and Sandmaier, {Brenda M.}",
year = "2013",
month = "9",
doi = "10.1016/j.bbmt.2013.06.002",
language = "English (US)",
volume = "19",
pages = "1340--1347",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Fludarabine and 2-Gy TBI is superior to 2Gy TBI as conditioning for HLA-Matched related hematopoietic cell transplantation

T2 - A phase III randomized trial

AU - Kornblit, Brian

AU - Maloney, David G.

AU - Storb, Rainer

AU - Storek, Jan

AU - Hari, Parameswaran

AU - Vucinic, Vladan

AU - Maziarz, Richard

AU - Chauncey, Thomas R.

AU - Pulsipher, Michael A.

AU - Bruno, Benedetto

AU - Petersen, Finn B.

AU - Bethge, Wolfgang A.

AU - Hübel, Kai

AU - Bouvier, Michelle E.

AU - Fukuda, Takahiro

AU - Storer, Barry E.

AU - Sandmaier, Brenda M.

PY - 2013/9

Y1 - 2013/9

N2 - The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in combination with 90mg/m2 fludarabine (FLU/TBI), before transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five patients with hematological malignancies were randomized to be conditioned with TBI alone (n=44) or FLU/TBI (n=41). All patients had initial engraftment. Two graft rejections were observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host disease (GVHD) were similar between groups. Three-year overall survival was lower in the TBI group (54% versus 65%; hazard ratio [HR], .57; P= .09), with higher incidences of relapse/progression (55% versus 40%; HR, .55; P= .06), relapse-related mortality (37% versus 28%; HR, .53; P= .09), and a lower progression-free survival (36% versus 53%; HR, .56; P= .05). Median donor T cell chimerism levels were significantly lower in the TBI group at days 28 (61% versus 90%; P

AB - The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in combination with 90mg/m2 fludarabine (FLU/TBI), before transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five patients with hematological malignancies were randomized to be conditioned with TBI alone (n=44) or FLU/TBI (n=41). All patients had initial engraftment. Two graft rejections were observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host disease (GVHD) were similar between groups. Three-year overall survival was lower in the TBI group (54% versus 65%; hazard ratio [HR], .57; P= .09), with higher incidences of relapse/progression (55% versus 40%; HR, .55; P= .06), relapse-related mortality (37% versus 28%; HR, .53; P= .09), and a lower progression-free survival (36% versus 53%; HR, .56; P= .05). Median donor T cell chimerism levels were significantly lower in the TBI group at days 28 (61% versus 90%; P

KW - Body irradiation

KW - Fludarabine/low dose total

KW - Hematopoietic cell

KW - HLA-matched related

KW - Nonmyeloablative conditioning

KW - Transplantation randomized

KW - Trial

UR - http://www.scopus.com/inward/record.url?scp=84882781560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882781560&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.06.002

DO - 10.1016/j.bbmt.2013.06.002

M3 - Article

C2 - 23769990

AN - SCOPUS:84882781560

VL - 19

SP - 1340

EP - 1347

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -